KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for Twist Bioscience (TWST) over the last 9 years, with Q4 2025 value amounting to $638.1 million.

  • Twist Bioscience's Liabilities and Shareholders Equity rose 484.82% to $638.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.5 billion, marking a year-over-year decrease of 174.35%. This contributed to the annual value of $641.9 million for FY2025, which is 448.27% up from last year.
  • As of Q4 2025, Twist Bioscience's Liabilities and Shareholders Equity stood at $638.1 million, which was up 484.82% from $641.9 million recorded in Q3 2025.
  • In the past 5 years, Twist Bioscience's Liabilities and Shareholders Equity ranged from a high of $1.0 billion in Q1 2022 and a low of $595.6 million during Q1 2025
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $714.1 million (2021), whereas its average is $751.0 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 10912.24% in 2021, then crashed by 2125.23% in 2024.
  • Quarter analysis of 5 years shows Twist Bioscience's Liabilities and Shareholders Equity stood at $786.2 million in 2021, then grew by 15.75% to $910.0 million in 2022, then decreased by 19.47% to $732.8 million in 2023, then fell by 16.95% to $608.6 million in 2024, then rose by 4.85% to $638.1 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $638.1 million for Q4 2025, versus $641.9 million for Q3 2025 and $643.6 million for Q2 2025.